Research programme: radiolabelled carbonic anhydrase IX inhibitors - Progenics Pharmaceuticals

Drug Profile

Research programme: radiolabelled carbonic anhydrase IX inhibitors - Progenics Pharmaceuticals

Alternative Names: 99mTc-MIP-1505; 99mTc/Re(CO)3 labelled benzenesulfonamide conjugates for molecular imaging of carbonic anhydrase IX - Progenics; Hypoxia-imaging radiopharmaceutical - Progenics; MIP-1267; MIP-1505; Small molecular inhibitor of CA IX radiolabelled with 99mTc - Progenics; Small-molecule benzenesulfonamide (BzSA) CA-IX inhibitors - Progenics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Class Benzene derivatives; Radiopharmaceutical diagnostics; Small molecules; Sulfonamides
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA
  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 23 Aug 2012 Pharmacodynamics data from a preclinical trial in Solid tumours (diagnosis of tumour hypoxia) presented at the 244th American Chemical Society National Meeting (244th-ACS-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top